Method for detecting ischemia modified albumin and detection kit

Abstract

The invention provides a method for detecting ischemia modified albumin. According to the method, the characteristic that the binding capacity of the ischemic modified albumin and the cobalt is weakened is utilized, free cobalt in a reaction system is detected by using chemical reagents, the change of the content of the free cobalt is expressed through the change of absorbance, the concentration of the ischemia modified albumin is indirectly expressed, and a color developing agent used in the detection is 2,4-dimercaptopyrimidine and is used for detecting the free cobalt in the reaction system. The method has the advantages that the stability of the color developing agent of the 2,4-dimercaptopyrimidine is higher, the analysis sensitivity is higher, the price is lower, the detection resultis reported based on the concentration of the free cobalt, and the problem that the absorbance of an IMA (ischemia modified albumin) detection result is unstable due to the fact that the performanceof instruments or reagents is different and unstable when the absorbance is adopted for report can be solved. The invention further provides a detection kit for the ischemia modified albumin. The detection kit comprises the reagents used in the method.

Description

Technical field [0001] The invention relates to a method for detecting ischemia-modified albumin in human serum, in particular to a method for determining ischemia-modified albumin and a detection kit. Background technique [0002] Ischemia modified albumin (ischemia modified albumin, IMA) is an ideal myocardial ischemia marker discovered in recent years and has unique advantages in the early diagnosis of acute coronary syndrome. Acute coronary syndromes (Acute coronary syndromes ACS) refers to the pathological phenomena of coronary atherosclerotic plaque shedding, platelet aggregation, and thrombosis that cause coronary artery stenosis and blockage, causing myocardial ischemia and infarction. From a clinical perspective, it covers A group of continuously progressing conditions, including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction. [0003] Human serum albumin (HSA) is a kind of circulating protein. Its amino ter...

AI Technical Summary

Problems solved by technology

Due to the variety of DTT on the market, the reagents themselves have certain differences, resulting in the test results often being unstable due to the manufacturer, reagent type, batch number, etc.

Moreover, the DTT solution has a relatively short refrigerated or frozen storage stability time

[0012] Chromogenic agent DTT analysis sensitivity: DTT is used as free cobalt chromogenic agent, and the slope of the standard curve is not high (compared with DTE), thus indicating that the resolution of using DTT as free cobalt chromogenic agent is obviously not high

[0013] (4) Reagent price: Due to the characteristics of DTT’s spatial structure, when it reacts with different concentrations of free cobalt, the optimum color development concentration is higher. According to the current market price, although the price per gram of DTT is not high, but due to the concentration used in the determination of DTT method Higher, so the price is slightly higher after making up the test solution using DTT to detect IMA (compared with DTE)

Although dithioerythritol DTE can solve the stability problem, its solubility is low, about 15.4g / l at 20°C, and it is easy to crystallize

Images